Detection of vancomycin levels in patients receiving telavancin but not vancomycin

Gelfand, Mikhail S.; Cleveland, Kerry O.; Memon, Kashif

doi:10.1093/jac/dkr448

Cited by 5 publications

(5 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the second phase of the investigation, the Synchron PETIA reported the highest percent theoretical values (ϳ50%) among the 4 platforms tested, which was consistent with previous literature (6,7). The Advia Centaur XP CMIA reported the next highest level (24.9 to 32.3%).…”

Section: Discussionsupporting

confidence: 88%

“…Gelfand et al initially reported the potential cross-reactivity of telavancin and the Synchron PETIA based on serum samples drawn from patients receiving telavancin therapy (6). Evans et al performed an in vitro analysis similar to the present study which demonstrated the Synchron PETIA reports theoretical vancomycin concentrations of approximately 61%, while the Vista PETIA reports 6 to 15% theoretical concentrations (7).…”

supporting

confidence: 55%

“…The previous reports by Gelfand et al and Evans et al suggested that the Synchron vancomycin immunoassay could be used to monitor serum telavancin concentrations (6,7). The present study suggests this is not be feasible for two reasons.…”

mentioning

confidence: 60%

“…One case series and one in vitro study previously demonstrated the Synchron and Vista PETIA can report vancomycin concentrations in telavancin samples (6,7). Gelfand et al initially reported the potential cross-reactivity of telavancin and the Synchron PETIA based on serum samples drawn from patients receiving telavancin therapy (6).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Variability in Telavancin Cross-Reactivity among Vancomycin Immunoassays

McConeghy

Liao

Clark

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Telavancin is a semisynthetic lipoglycopeptide with a dual mechanism of action against Gram-positive pathogens. Two brief reports have suggested potential cross-reactivity of telavancin with the vancomycin particle-enhanced turbidometric immunoassay (PETIA). The purpose of this study was to evaluate several commercially available vancomycin immunoassays (fluorescence polarization [FPIA], enzyme-multiplied immunoassays [EMIT], PETIA, and chemiluminescent immunoassay [CMIA]) for cross-reactivity with telavancin. Seven sites were selected to analyze serum samples for vancomycin. Each site received a set of samples (n ‫؍‬ 18) which combined drug-free serum with telavancin, 7-OH telavancin metabolite, or vancomycin. Immunoassays demonstrating potential cross-reactivity were further evaluated by sending a duplicate sample set to multiple laboratories. Cross-reactivity was defined as the percent theoretical concentration (reported concentration/theoretical concentration ؋ 100). No cross-reactivity was seen with FPIA or EMIT. Within the theoretical concentration range of 5 to 120 g/ml of telavancin, the Synchron PETIA system reported vancomycin concentrations ranging from 4.7 to 54.2 g/ml compared to vancomycin concentrations from 1.1 to 5.6 g/ml for the Vista PETIA system. The Architect CMIA system reported vancomycin concentrations in the range of 0.27 to 0.97 g/ml, whereas Advia Centaur XP CMIA reported vancomycin concentrations between 1.6 and 31.6 g/ ml. The Architect CMIA immunoassay had the lowest percent cross-reactivity (0.8 to 5.4%), while the Synchron PETIA immunoassay demonstrated the highest percent cross-reactivity (45.2 to 53.8%). Telavancin samples measured by liquid chromatography-mass spectroscopy were within 93.9 to 122% of theoretical concentrations. Vancomycin concentrations were not measured in any 7-OH telavancin-spiked sample. Vancomycin concentrations measured by liquid chromatography-mass spectroscopy were within 57.2 to 113% of theoretical concentrations. PETIA and CMIA measured vancomycin concentrations in telavancinspiked samples. Significant variability in percent cross-reactivity was observed for each platform regardless of immunoassay method.

show abstract

Section: Discussionsupporting

confidence: 88%

supporting

confidence: 55%

mentioning

confidence: 60%

mentioning

confidence: 99%

See 2 more Smart Citations

Variability in Telavancin Cross-Reactivity among Vancomycin Immunoassays

McConeghy

Liao

Clark

et al. 2014

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…At concentrations ≥ 0.05 μg/ml but < 1.3, VAN levels were detectable, but CVs were > 15%. None of the patients was receiving concomitant therapy with telavancin, which can cause false‐positive VAN levels when utilizing a particle‐enhanced turbidimetric inhibition immunoassay …”

Section: Methodsmentioning

confidence: 99%

Risk Factors for Systemic Vancomycin Exposure Following Administration of Oral Vancomycin for the Treatment of Clostridium difficile Infection

et al. 2015

View full text Add to dashboard Cite

Serum VAN levels were detected in 58 (68.2%) of 85 patients receiving POV for CDI. Risk factors for systemic exposure to VAN following administration of POV included ICU admission; VAN dosages > 500 mg/day; administration ≥ 10 days or as retention enemas; and the presence of severe CDI, renal dysfunction, or inflammatory conditions of the GI tract. Unique to our study, we identified ICU admission and the concomitant use of VAN retention enemas to be significant risk factors for systemic exposure to VAN.

show abstract

Does oral vancomycin use necessitate therapeutic drug monitoring?

Cimolai

2019

Infection

View full text Add to dashboard Cite

Detection of vancomycin levels in patients receiving telavancin but not vancomycin

Cited by 5 publications

References 2 publications

Variability in Telavancin Cross-Reactivity among Vancomycin Immunoassays

Variability in Telavancin Cross-Reactivity among Vancomycin Immunoassays

Risk Factors for Systemic Vancomycin Exposure Following Administration of Oral Vancomycin for the Treatment of Clostridium difficile Infection

Does oral vancomycin use necessitate therapeutic drug monitoring?

Contact Info

Product

Resources

About